We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

98 hedge funds and large institutions have $176M invested in Aratana Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 28 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more call options, than puts

Call options by funds: $17K | Put options by funds: $4K

39% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less funds holding

Funds holding: 10398 (-5)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

37% less capital invested

Capital invested by funds: $279M → $176M (-$103M)

Holders
98
Holders Change
-5
Holders Change %
-4.85%
% of All Funds
2.57%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
15
Increased
39
Reduced
28
Closed
19
Calls
$17K
Puts
$4K
Net Calls
+$13K
Net Calls Change
-$141K

PETX Hedge Fund Activity: Q4 2015 in Review

98 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2015, worth a combined $176M — down 37% from $279M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PETX and 15 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 39 added.

The largest buyer was Broadfin Capital, adding an estimated $14M. The largest seller was Wellington Management Group, cutting an estimated $12.5M.

  • 98 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2015, down from 103 in Q3 2015.
  • Funds reported $176M of Aratana Therapeutics, Inc. stock for Q4 2015, down 37% quarter-over-quarter.
  • 15 funds opened new Aratana Therapeutics, Inc. positions in Q4 2015 and 19 closed out, a net change of -4 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q4 2015 was Broadfin Capital, an estimated $14M added.
  • The largest Aratana Therapeutics, Inc. seller in Q4 2015 was Wellington Management Group, an estimated $12.5M sold.

Based on aggregated 13F filings for Q4 2015.